Open AccessTargeting of CD122 enhances antitumor immunity by altering the tumor immune environment
Author(s) -
Daniel O. Villarreal,
Michael J. Allegrezza,
Melissa Smith,
Diana Chin,
Leopoldo Luistro,
Linda A. Snyder
Publication year - 2017
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.22642
Subject(s) - immunotherapy , cancer immunotherapy , cancer research , monoclonal antibody , immune system , cd8 , immunology , antigen , cytolysis , cytotoxic t cell , t cell , medicine , biology , antibody , in vitro , biochemistry
Mounting evidence demonstrates that CD8 + CD122 + T cells have suppressive properties with the capacity to inhibit T cell responses. Therefore, these cells are rational targets for cancer immunotherapy. Here, we demonstrate that CD122 monoclonal antibody (mAb; aCD122) therapy significantly suppressed tumor growth and improved long-term survival in tumor-bearing mice. This therapeutic effect correlated with enhanced polyfunctional, cytolytic intratumoral CD8 + T cells and a decrease in granulocytic myeloid-derived suppressor cells (G-MDSCs). In addition, aCD122 treatment synergized with a vaccine to augment vaccine-induced antigen (Ag)-specific CD8 + T cell responses, reject established tumors and generate memory T cells. Furthermore, aCD122 mAb synergized with an anti-GITR (aGITR) mAb to confer significant control of tumor growth. These results suggest CD122 might be a promising target for cancer immunotherapy, either as a single agent or in combination with other forms of immunotherapy.